Feb 10, 2017 13:01 pm UTC| Business
BEVERLY, Mass., Feb. 10, 2017 -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and...
Feb 10, 2017 13:01 pm UTC| Business
BEVERLY, Mass., Feb. 10, 2017 -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and...
Catalyst Biosciences Announces 1-for-15 Reverse Stock Split
Feb 10, 2017 13:01 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2017 -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced...
Intellipharmaceutics Announces 2016 Year End Results
Feb 10, 2017 13:01 pm UTC| Business
TORONTO, Feb. 10, 2017 -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of...
Catalyst Biosciences Announces 1-for-15 Reverse Stock Split
Feb 10, 2017 13:01 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2017 -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced...
Intellipharmaceutics Announces 2016 Year End Results
Feb 10, 2017 13:00 pm UTC| Business
TORONTO, Feb. 10, 2017 -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of...
Immune Design to Present at Upcoming Investor Conferences
Feb 10, 2017 13:00 pm UTC| Business
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 10, 2017 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that Carlos Paya, M.D., Ph.D., President and Chief...